Clinical trials: Glucagon
Obesity
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with…
- Trial name
- GZBF (NCT07467447)
- Testing
- Retatrutide (LY3437943), Standardized diet and physical activity counseling throughout the study.
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Hudson Biotech
Duchenne Muscular Dystrophy (DMD)
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD) is a rare, genetic disease that leads to muscle weakness, breathing difficulties, heart disease, and early death.
- Trial name
- NCT07642635
- Testing
- Semaglutide (Rybelsus®)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt University Medical Center
Diabetes Insipidus
Copeptin After a Subcutaneous Stimulation With Glucagon in Adults
This study is to evaluate copeptin values after the subcutaneous injection of glucagon in adults (healthy volunteers and patients with diabetes insipidus or primary polydipsia).
- Trial name
- Glucacop (NCT04550520)
- Testing
- Glucagon
- Where
- Switzerland
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Type 2 Diabetes, Obesity
Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes
The study seeks to explore the cardiovascular effects of co-agonism at the glucagon and (glucagon-like peptide-1) GLP-1 receptor. Glucagon and exenatide will be intravenously infused into participants with type 2 diabetes (T2DM).
- Trial name
- COCONUT (NCT04307797)
- Testing
- 0.9% Sodium-chloride, Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min, Glucagon 12.5ng/kg/min and 0.9% saline
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Type 2 Diabetes, Type 1 Diabetes
The Effect of GLP-1 on the Inhibition of Glucagon Secretion
Diabetes(both types) are recognized by high levels of glucagon in the circulation. Glucagon is known to increase blood glucose, and might therefore contribute to the respective diseases.
- Trial name
- NCT01507597
- Testing
- Native human Glucagon-like Peptide-1 ( GLP-1(7-36)), NaCl
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Maturity-Onset Diabetes of the Young, Type 3
The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea
The most prevalent monogenetic diabetic subtype is named maturity onset diabetes of the young type (MODY3) or hepatocyte nuclear factor 1α (HNF1A)-diabetes.
- Trial name
- HNF1A-Clamp (NCT03081676)
- Testing
- Glimepiride 1Mg Tablet, Glucagon-like Peptide-1, Glucose-Dependent Insulinotropic Polypeptide
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type 1 Diabetes Mellitus
Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon
This study will test the hypothesis that a BAC (blood alcohol content) of 0.1% will not significantly alter the anti-hypoglycemic effect of mico-dose glucagon in individuals with type 1 diabetes.
- Trial name
- NCT02516150
- Testing
- Ethanol, Glucagon
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Massachusetts General Hospital
Obesity
To Determine Tolerability to Glucagon Infusion in Obese Subjects
To further understand the tolerability of glucagon.
- Trial name
- GIO (NCT02817659)
- Testing
- Glucagon
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Diabetes Mellitus
Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) Therapy
The purpose of this study is to compare the effect of a single administration of a DPP-IV inhibitor (vildagliptin: Galvus ®) versus no treatment over two populations of diabetic patients: without diabetic autonomic neuropathy…
- Trial name
- DPPNAC (NCT01452113)
- Testing
- Vildagliptin
- Where
- France
- Volunteers
- 21 people
- Sponsor
- University Hospital, Toulouse
Diabetes After Total Pancreatectomy
Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism
Patients with diabetes are characterised not only by compromised insulin secretion and action, but also by elevated plasma levels of the 29-amino acid peptide hormone glucagon, which hitherto has been considered a…
- Trial name
- PX-GRA (NCT02944110)
- Testing
- Glucagon receptor antagonist LY2409021
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type 1 Diabetes Mellitus
Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver
The purpose of this study is to learn if giving multiple doses of a hormone called glucagon can cause a major decrease in liver glycogen (animal starch).
- Trial name
- NCT01986231
- Testing
- Glucagon
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Legacy Health System
Type 1 Diabetes
Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone
This study aims to test an insulin and glucagon delivery algorithm designed to be used in conjunction with a continuous glucose monitoring system.
- Trial name
- NCT00797823
- Testing
- Insulin, Asp(B28)-, Glucagon
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Legacy Health System
Diabetes Mellitus, Type 1, Hypoglycemia
Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes
Approximately 25% of patients with type 1 diabetes have lost the capacity to timely detect hypoglycaemia, a condition referred to as impaired hypoglycaemic awareness (IHA) that causes a six-fold higher risk of severe, potentially…
- Trial name
- NCT02735031
- Testing
- Exenatide
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Radboud University Medical Center
Diabetes Mellitus, Type 1
Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents
This study will be looking to confirm the effect of dasiglucagon when compared with glucagon for treating very low sugar levels in Asian adults with T1D and the effect of dasiglucagon in Japanese adolescents with T1D.
- Trial name
- NCT06588504
- Testing
- Dasiglucagon, Glucagon
- Where
- Japan
- Volunteers
- 38 people
- Sponsor
- Novo Nordisk A/S
Short Bowel Syndrome
Short Bowel Syndrome and Teduglutide Versus Placebo
This research study was done to see what the effects are of Teduglutide on people with short bowel syndrome (SBS). Teduglutide is a synthetic medication administered as an injection, which has shown to increase intestinal blood…
- Trial name
- NCT02099084
- Testing
- Teduglutide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Hypoglycemia, Diabetes Mellitus
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
Up to two hundred (200) adult participants with type 1 diabetes (T1D) aged 18 to 75 years will be selected for inclusion in the study.
- Conditions
- Hypoglycemia, Diabetes Mellitus, Drug-Specific Antibodies
- Trial name
- NCT02171130
- Testing
- Nasal Glucagon
- Where
- 9 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- Eli Lilly and Company
Diabetic Kidney Disease
The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease
Diabetic kidney disease (DKD) is a devastating complication of diabetes, that in it's worst form, can lead to early cardiovascular death or kidney failure.
- Trial name
- NCT01847313
- Testing
- Liraglutide
- Where
- Ireland
- Volunteers
- 20 people
- Sponsor
- Karl Neff
Diabetes After Total Pancreatectomy
The Effect of Insulin-induced Hypoglycaemia on Gut-derived Glucagon Secretion (Px-Hypo)
The overall objective of this study is to investigate whether hypoglycaemia (the most potent stimulus of pancreatic glucagon secretion) affects the secretion of gut-derived glucagon in totally pancreatectomized patients.
- Trial name
- NCT04064203
- Testing
- Oral glucose tolerance test, Clamp experiment
- Where
- Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Diabetes Mellitus Type 1
ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon
The trial is a single-centre, randomised, sequential, cross-over trial assessing pharmacokinetic and pharmacodynamic responses after micro-doses of ZP4207 (dasiglucagon*) administered subcutaneously to patients with type 1…
- Trial name
- NCT02916251
- Testing
- ZP4207(dasiglucagon) glucagon analogue, Glucagon (Native glucagon)
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Zealand Pharma
Diabetes
Vildagliptin and the Glucagon Response to Hypoglycemia in Insulin-Treated Patients With Type 2 Diabetes
The purpose of this study is to explore whether the novel therapy of type 2 diabetes, vildagliptin, which inhibits dipeptidyl peptidase-4 (DPP-4), affects glucagon counterregulation during hypoglycemia in insulin-treated patients…
- Trial name
- NCT01219400
- Testing
- Vildagliptin
- Where
- Sweden
- Volunteers
- 28 people
- Sponsor
- Lund University